Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

@article{Boer2010VandetanibWD,
  title={Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study},
  author={K. T. den Boer and Istv{\'a}n L{\'a}ng and Antonio Llombart-Cussac and Inger Andreasson and Guillermo L{\'o}pez Vivanco and Nick Sanders and Gillian M. Pover and Elizabeth E Murray},
  journal={Investigational New Drugs},
  year={2010},
  volume={30},
  pages={681-687}
}
Purpose The aim of this Phase II study was to assess the efficacy and safety of vandetanib in combination with docetaxel in patients with pretreated advanced breast cancer. Methods The primary study objective was to compare the number of progression events in patients receiving once-daily oral vandetanib (100 mg) in combination with docetaxel (100 mg/m2 iv… CONTINUE READING